within Pharmacolibrary.Drugs.ATC.C;

model C10AC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 4000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Colestyramine (also known as cholestyramine) is an anion-exchange resin used to lower cholesterol levels and to treat pruritus associated with partial biliary obstruction. It is also used for the management of bile acid-induced diarrhea. The drug is administered orally and is generally considered safe, though it is largely superseded by more modern lipid-lowering agents for primary hypercholesterolemia. It is still approved and used clinically today for specified indications.</p><h4>Pharmacokinetics</h4><p>Colestyramine is a non-absorbed resin and acts locally in the gastrointestinal tract; systemic pharmacokinetic parameters (e.g. bioavailability, volume of distribution, clearance) are not applicable, as it is not systemically absorbed in healthy adults.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00002&quot;>10.2165/00003088-200544050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871634/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Davies, NM, &amp; Anderson, KE (1997). Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. <i>Clinical pharmacokinetics</i> 33(3) 184–213. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199733030-00003&quot;>10.2165/00003088-199733030-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9314611/&quot;>https://pubmed.ncbi.nlm.nih.gov/9314611</a></p></li><li><p>Proudfoot, AT (2003). Pentachlorophenol poisoning. <i>Toxicological reviews</i> 22(1) 3–11. DOI:<a href=&quot;https://doi.org/10.2165/00139709-200322010-00002&quot;>10.2165/00139709-200322010-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14579543/&quot;>https://pubmed.ncbi.nlm.nih.gov/14579543</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AC01;
